Literature DB >> 34031097

Autoimmune heparin-induced thrombocytopenia: a rare manifestation of COVID-19.

Katherine Julian1, Donald Bucher2, Rohit Jain2.   

Abstract

We describe the case of a 65-year-old male who presented to an outside hospital for shortness of breath, nausea and vomiting 8 days after testing positive for COVID-19. Initial workup revealed massive bilateral pulmonary emboli and thrombocytopenia. The patient was then admitted to our hospital, received an inferior vena cava filter and initially started on argatroban for autoimmune heparin-induced thrombocytopenia (HIT) prophylaxis. On hospital stay day 6, labs revealed a diagnosis of HIT in the setting of COVID-19. This case highlights the rare occurrence of a patient developing HIT without heparin exposure and in the setting of a novel infectious agent, COVID-19. © BMJ Publishing Group Limited 2021. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  COVID-19; haematology (drugs and medicines); haematology (incl blood transfusion)

Mesh:

Substances:

Year:  2021        PMID: 34031097     DOI: 10.1136/bcr-2021-243315

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  2 in total

1.  Heparin-induced thrombocytopenia in patients with COVID-19: a systematic review and meta-analysis.

Authors:  Noppacharn Uaprasert; Nuanrat Tangcheewinsirikul; Ponlapat Rojnuckarin; Rushad Patell; Jeffrey I Zwicker; Thita Chiasakul
Journal:  Blood Adv       Date:  2021-11-09

2.  A case of severe COVID-19 with pulmonary thromboembolism related to heparin-induced thrombocytopenia during prophylactic anticoagulation therapy.

Authors:  Kosaku Sasaki; Masayuki Murata; Keiji Nakamura; Yuji Matsumoto; Yuko Nakashima; Sho Yamasaki; Azusa Ota; Satoshi Hiramine; Koji Takayama; Hiroaki Ikezaki; Kazuhiro Toyoda; Eiichi Ogawa; Nobuyuki Shimono
Journal:  J Infect Chemother       Date:  2022-05-11       Impact factor: 2.065

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.